Early day motion tabled by primary sponsor Angus Brendan MacNeil (Scottish National Party), on Thursday, 4 February 2021, in the House of Commons. It is signed by 9 members in total.
Treatment options for multiple sclerosis patients
That this House welcomes the Scottish Medicines Consortium’s approval of ozanimod for Scottish patients with relapsing remitting multiple sclerosis; notes that patients in Scotland will be the first in the UK to have access to this new treatment option; recognises that not all therapies work for all MS patients so it is vital to have access to all therapy options to improve patient outcomes and patient choice; looks forward to patients in the rest of the UK being afforded similar access; stresses the importance that patient and clinician perspectives are considered and incorporated into decisions on approving access to new treatments; and commends the healthcare professionals and charities that support patients with this debilitating disease, particularly during the covid-19 pandemic.
Secondary information
- Type
- Early day motion
- Reference
- 1447
- Session
- 2019-21
- Other sponsors
- Jonathan Edwards
- Chris Stephens
- Steven Bonnar
- Allan Dorans
- Kenny MacAskill
- Subjects
- Medical treatments Multiple sclerosis
- Link
- View this Early day motion on edm.parliament.uk
Librarians' tools
- Timestamp
- 2022-02-14 21:04:07 +0000
- URI
- http://data.parliament.uk/edms/58059
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/edms/58059
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/edms/58059